"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
Descriptor ID |
D003841
|
MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells. Cells. 2021 04 28; 10(5).
-
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. 2020 10 23; 22(1):111.
-
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. Anticancer Res. 2016 09; 36(9):4771-6.
-
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014 May 15; 106(5).
-
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010 May 01; 16(9):2634-45.
-
[Requirements for the development of molecularly defined targeted therapy in oncology]. Med Klin (Munich). 2006 Aug 15; 101(8):617-23.